This is a standardized extract of Ginkgo biloba leaves, supplied as a powder and built to the established 24/6 specification: not less than 24.0% flavone glycosides and not less than 6.0% total terpene lactones. It concentrates the two compound families that make ginkgo leaf distinctive - flavonoids and terpenoids - which are not found together in this way in other plants. Research first documented in Germany about three decades ago identified bioactivities linked to these compounds, including effects on cerebral function and peripheral circulation, and standardized ginkgo leaf extract has since become one of the most widely used botanical functional materials worldwide.
Ginkgo biloba itself is a tree of exceptional resilience. The species appeared roughly 250 million years ago, survived the ice ages, and individual trees can live for thousands of years - a botanical 'living fossil' prized in Japan, where it accounts for a large share of street trees and turns brilliant gold each autumn.
Ginkgolic acids are the alkylphenol fraction of ginkgo leaf associated with allergic skin reactions. In this extract they are almost entirely removed and controlled to 1 ug/g (1 ppm) or less - five times stricter than the 5 ppm limit normally applied to pharmaceutical-grade ginkgo. This is one of the defining quality features of the material.
The extract is produced through integrated in-house manufacturing from specially cultivated, carefully selected ginkgo leaves, with a verified Japanese-origin leaf option for full raw-material traceability. The process is designed to keep the flavonoid and terpenoid fractions in balance while stripping ginkgolic acid down to the 1 ppm level.
Powder supplied in 1 kg and 10 kg packs. Shelf life is 2 years from manufacture, unopened at room temperature. Store in an airtight container away from heat and humidity; after opening, protect from moisture and use promptly.
Standardized Ginkgo biloba leaf extracts defined by roughly 24% flavone glycosides and 6% terpene lactones - the EGb 761-type extract - are the form behind ginkgo's clinical record. The European Union herbal monograph (EMA) recognizes a refined dry extract quantified to 22-27% ginkgo flavone glycosides (quercetin, kaempferol, isorhamnetin) and 5-7% terpene lactones (ginkgolides A/B/C 2.8-3.4%, bilobalide 2.6-3.2%), with ginkgolic acids less than 5 ppm. This material sits in that same standardization band, at a stricter 1 ppm ginkgolic-acid level.
The two active fractions work through different routes. The flavonoids (for example quercetin) carry most of the antioxidant and free-radical-scavenging activity, while the terpene lactones (ginkgolides) act as platelet-activating-factor (PAF) antagonists; in a neuronal cell model, both fractions contributed to protection against beta-amyloid toxicity (Shi et al., Chemico-Biological Interactions, 2009).
Several meta-analyses of randomized, placebo-controlled trials report that the standardized extract at 240 mg/day is superior to placebo for cognition, activities of daily living and global clinical assessment in cognitive impairment and dementia, with tolerability comparable to placebo (Gauthier and Schlaefke, Clinical Interventions in Aging, 2014; Tan et al., Journal of Alzheimer's Disease, 2015; Riepe et al., World Journal of Biological Psychiatry, 2025). This evidence describes the standardized extract as studied in trials; it is not a claim about any particular finished product, and permitted claims depend on the destination market.
Independent analyses repeatedly find ginkgo supplements adulterated - flavonol aglycones or rutin and quercetin added to inflate the measured flavonol content. In one study only 3 of 14 commercial finished products were authentic (Ma et al., Phytomedicine, 2016); a USDA-led fingerprinting study likewise flagged rutin- and quercetin-spiked products (Harnly et al., Journal of AOAC International, 2012). Authentic, traceable material removes the single largest quality-assurance risk in the category - failed identity testing and recalls.
Ginkgolic acids are allergenic alkylphenols, which is why pharmacopeial and pharmaceutical practice caps them at 5 ppm or less in ginkgo extract. Holding them to 1 ppm or less puts this material in the safest tier and clears even the strictest market and pharmaceutical limits.
Standardized ginkgo leaf extract is also recognized outside human supplements: a dried Ginkgo biloba leaf extract is authorized in the EU as a feed additive for cats and dogs, supporting the growing pet cognitive-health category.
It is standardized to 24.0% or more flavone glycosides and 6.0% or more total terpene lactones (ginkgolides A, B, C and bilobalide) - the established 24/6 specification used for clinically studied standardized ginkgo extracts. Ginkgolic acid is controlled to 1 ppm or less.
Ginkgolic acids are allergenic alkylphenols linked to skin sensitization. The usual pharmaceutical limit is 5 ppm or less; this extract is held to 1 ppm or less, five times stricter, so it passes the strictest market and pharmaceutical limits and lowers contact-allergy risk.
It is supplied as a bulk raw material in 1 kg and 10 kg packs. In Japan it fits the FFC route for memory and cognition; in the United States it is used as a dietary-supplement ingredient. In the EU and UK, ginkgo leaf dry extract is frequently regulated as a herbal medicine and the food-supplement route is restricted, so confirm classification for your market. Reference intake is 60-240 mg/day.
Authenticity is the core of this material. Product specifications (flavone glycosides, terpene lactones, ginkgolic acid) and an MSDS are available now, with a Certificate of Analysis on request; a Japanese-origin leaf option adds full traceability - valuable in a category where independent studies find a large share of products adulterated.
